X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections, but future pipeline remains challenging

By Andrew Powaleny  |    April 29, 2021
The discovery and introduction of antibiotics in the 1940s transformed modern medicine and enabled tremendous progress in health care and life expectancy. Today, this progress is being threatened...   Read More

New data from insurers show detriments of copay accumulator adjustment programs

By Katie Koziara  |    April 28, 2021
Commercial health insurers are starting to admit what the biopharmaceutical research industry has been warning for some time: copay accumulator adjustment programs hurt patient outcomes and shift...   Read More

Patient safety is at the heart of COVID-19 vaccine R&D

By Richard Moscicki, M.D.  |    April 26, 2021
As the world continues to feel the impact of the COVID-19 pandemic, the biopharmaceutical industry is continuing working around the clock to research, develop and manufacture vaccines to prevent...   Read More

Data shows that Americans are relying on vaccines to get us through the pandemic

By Mark Keida  |    April 22, 2021
As we continue to combat the pandemic, America’s biopharmaceutical industry is working around the clock in unprecedented partnerships to manufacture COVID-19 vaccines, reaching billions of doses...   Read More

West Virginia becomes the first state to lower patient costs by sharing the savings

By Scott LaGanga  |    April 20, 2021
In a historic moment for patient affordability, last week West Virginia became the first state in the nation to adopt ground-breaking legislation, HB2263, requiring insurers and their PBMs to...   Read More

What they are saying: Experts highlight the importance of IP in recent NIST proposal comments

By Megan Van Etten  |    April 20, 2021
Strong, reliable, and clearly defined intellectual property (IP) protections are the foundation of America’s robust innovation ecosystem that patients across the globe rely on for the research and...   Read More

PhRMA member companies share how they are improving clinical trial diversity

By Dr. Freda Lewis-Hall  |    April 14, 2021
As part of the biopharmaceutical industry’s efforts to improve health outcomes for patients in underserved communities, PhRMA member companies are identifying ways to improve clinical trial...   Read More

Our three-part approach to build a better health care system

By Stephen J. Ubl  |    April 13, 2021
On April 3, more than four million Americans received a COVID-19 vaccine — the largest single-day vaccination event in human history. For innovators across the pharmaceutical industry, these...   Read More

ICYMI: New CBO Report highlights biopharmaceutical leadership in the development of new treatments and cures

By Andrew Powaleny  |    April 12, 2021
America’s biopharmaceutical companies are at the heart of a research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. The ongoing...   Read More

Diversifying clinical trials and fighting disease requires equity and trust

By Rebecca Marklund  |    April 12, 2021
The COVID-19 pandemic has left no person unaffected, but Black Americans have been disproportionately impacted. Black adults are nearly four times more likely to be hospitalized from the virus and...   Read More

Key excerpts: PhRMA submits comments to NIST in effort to safeguard intellectual property protections

By Megan Van Etten  |    April 9, 2021
Earlier this week PhRMA submitted comments to the National Institute of Standards and Technology (NIST) regarding the proposed rulemaking on implementing regulations of the Bayh-Dole Act. Passed...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates